Literature DB >> 16840365

Treating asthma as an inflammatory disease.

G Walter Canonica1.   

Abstract

Asthma is a chronic inflammatory disease involving many different cell types and cellular elements. Evidence suggests that, in the long term, this inflammation leads to remodeling of the airways, airflow obstruction, and the bronchial hyperreactivity symptoms of asthma, and is present even in patients with intermittent disease. Patients with allergic asthma and those with seasonal allergic rhinitis are believed to have minimal persistent inflammation, and the two diseases often occur together. Early intervention with inhaled corticosteroids (ICS) is believed to modify the disease process and may limit long-term remodeling. ICS remain the cornerstone and "gold standard" of treatment for asthma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16840365     DOI: 10.1378/chest.130.1_suppl.21S

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer.

Authors:  R Ranjha; J Paul
Journal:  Inflamm Res       Date:  2013-02-17       Impact factor: 4.575

2.  Disease Trajectories for Hidradenitis Suppurativa in the Danish Population.

Authors:  Rune Kjærsgaard Andersen; Isabella Friis Jørgensen; Roc Reguant; Gregor Borut Ernst Jemec; Søren Brunak
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

3.  Intranasal challenge with increasing ovalbumin doses differently affects airway hyperresponsiveness and inflammatory cell accumulation in mouse model of asthma.

Authors:  Berislav Bosnjak; Vanesa Ivetić Tkalcević; Koraljka Durić; Daniela Belamarić; Snjezana Cuzić; Zeljko Ferencić; Karmen Brajsa; Ines Glojnarić; Roberto Antolović; Boska Hrvacić
Journal:  Inflamm Res       Date:  2009-05-08       Impact factor: 4.575

Review 4.  Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide.

Authors:  Rüdiger Nave
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

5.  Effect of coadministered ketoconazole, a strong cytochrome P450 3A4 enzyme inhibitor, on the pharmacokinetics of ciclesonide and its active metabolite desisobutyryl-ciclesonide.

Authors:  Gabriele M Böhmer; Anton Drollmann; Christoph H Gleiter; Rüdiger Nave
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues.

Authors:  Paolo Montuschi
Journal:  Front Pharmacol       Date:  2011-07-14       Impact factor: 5.810

7.  Metabolism of ciclesonide in the upper and lower airways: review of available data.

Authors:  Ruediger Nave; Nigel McCracken
Journal:  J Asthma Allergy       Date:  2008-09-07

8.  Hyperthyroidism and risk for bipolar disorders: a nationwide population-based study.

Authors:  Li-Yu Hu; Cheng-Che Shen; Yu-Wen Hu; Mu-Hong Chen; Chia-Fen Tsai; Huey-Ling Chiang; Chiu-Mei Yeh; Wei-Shu Wang; Pan-Ming Chen; Tsung-Ming Hu; Tzeng-Ji Chen; Tung-Ping Su; Chia-Jen Liu
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

9.  Tristetraprolin Down-Regulation Contributes to Persistent TNF-Alpha Expression Induced by Cigarette Smoke Extract through a Post-Transcriptional Mechanism.

Authors:  Xue-Ke Zhao; Pulin Che; Ming-Liang Cheng; Quan Zhang; Mao Mu; Hong Li; Yuan Luo; Yue-Dong Liang; Xin-Hua Luo; Chang-Qing Gao; Patricia L Jackson; J Michael Wells; Yong Zhou; Meng Hu; Guoqiang Cai; Victor J Thannickal; Chad Steele; J Edwin Blalock; Xiaosi Han; Ching-Yi Chen; Qiang Ding
Journal:  PLoS One       Date:  2016-12-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.